✦ LIBER ✦

22LBA Overall survival analyses from the SATURN phase III placebo-controlled study of erlotinib as first-line maintenance therapy in advanced non-small-cell lung cancer (NSCLC)

✍ Scribed by F. Cappuzzo; B. Coudert; R. Wierzbicki; K. Park; F. Custers; G.A. Curbera; G. Giaccone; W. Hilbe; G. Klingelschmitt; T.E. Ciuleanu

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

8LBA Biomarker evaluation in the randomi

✍ B. Johnson; V. Miller; L. Amler; H. Stern; C. Soh; P. O'Connor; F. Kabbinavar 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 68 KB

PD-068 An exploratory analysis of a phas

✍ Bunn, P.; Rosell, R.; Fossella, F.; Perry, M.; Stahel, R.; Barata, F.; Nguyen, B 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 142 KB

EGFR expression as a predictor of surviv

✍ Robert Pirker; Jose R Pereira; Joachim von Pawel; Maciej Krzakowski; Rodryg Raml 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 872 KB

O-51 Phase III study (TAX 326) of doceta

✍ Belani, Chandra P.; Fossella, Frank V. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 180 KB

OP78 EGFR mutations based on circulating

✍ N. Yamamoto; Y. Ichinose; Y. Nishiwaki; Y. Ohe; K. Nishio; H. Jiang; E. Duffield 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 40 KB